Risk factors and glycation end products in patients with different forms of coronary heart disease and type 2 diabetes mellitus

Cite item

Full Text


Aim. To determine the levels of growth factors and glycation end products in patients with different forms of coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). Subjects and methods. A total of 134 patients with CHD and T2DM, including 38 patients with non-ST-elevation acute coronary syndrome (ACS), were examined. The arterial and venous serum levels of basic fibroblast growth factor-β (FGF-β), transforming growth factor-β (TGF-β), placental growth factor (PlGF), advanced glycation end products (AGEs) and their receptors (RAGE) were estimated in all the patients. Results. A direct correlation was found between the degree of arterial stenosis and the level of growth factors and AGEs in the patients with T2DM; there was also a direct correlation of the examined factors with lipid metabolic parameters. There was a significant two-fold increase in FGF-β, PlGF, and RAGE levels in the patients with ACS. Conclusion. Hyperglycemia was found to negatively affect the progression of atherosclerotic changes in the vessel wall and on that of fibrotic processes.


  1. Калашникова М.Ф., Сунцов Ю.И., Белоусов Д.Ю., Кантемирова М.А. Анализ эпидемиологических показателей сахарного диабета 2 типа среди взрослого населения города Москвы. Сахарный диабет. 2014;3:5-16.
  2. Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16(2):159-178.
  3. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol. 2010;42:535-542.
  4. Baird A, Bohlen P. Fibroblast Growth Factors. Fibroblast Growth Factors in Peptide Growth Factors and their Receptors. New York: Springer Verlag; 1990:369-418.
  5. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001;49(3):507-521.
  6. Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE. Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol. 1991;86(3):25-31.
  7. Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest. 1994;93:2372-2378.
  8. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001;49;3:507-521.
  9. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des. 2008;14(10):979-986.
  10. Bartnik M, Ryden L, Ferrari R. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25(21):1880-1890.
  11. Peppa M, Raptis SA. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev. 2008;4(2):92-100.
  12. Nin JW, Jorsal A. Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All—Cause Mortality in Type 1 Diabetes. Diabetes Care. 2011;34:442-447.
  13. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4(5):285-293.
  14. Tiyyagura SR, Pinney SP. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt Sinai J Med. 2006;73(6):840-851.
  15. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor beta. Cardiovasc Res. 2005;65:694-701.
  16. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T. Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure. J Cardiac Fail. 2008;14;2:133-139.
  17. Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DA. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012;34;2:222-228.
  18. Takeda Y, Uemura S. Treatment with Recombinant Placental Growth Factor Enhances both Angiogenesis and Arteriogenesis and Improves Survival after Myocardial Infarction. Circulation. 2006;114:63.
  19. Liu X, Caluwe E, Reyns G. Placental Growth Factor Increases Regional Myocardial Blood Flow and Function in a New Porcine Model of Chronic Myocardial Ischemia. Circulation. 2009;120:837.
  20. Nutu O, Molinie V. Therapeutic Role of Placenta Growth Factor in Post-Infarct Myocardial Revascularization. Circulation. 2006;114:72.
  21. Falcone C, Bozzini S, Falcone R, Pelissero G. Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Atherosclerosis: Possible Correlation with Clinical Presentation. Dis Markers. 2013;35(3):135-140.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies